» Articles » PMID: 39005234

TRIM65/NF2/YAP1 Signaling Coordinately Orchestrates Metabolic and Immune Advantages in Hepatocellular Carcinoma

Overview
Journal Adv Sci (Weinh)
Date 2024 Jul 15
PMID 39005234
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths worldwide. Significantly activated uridine nucleotide and fatty acid metabolism in HCC cells promote malignant proliferation and immune evasion. Herein, it is demonstrated that the tripartite motif 65 (TRIM65) E3 ubiquitin-protein ligase, O-GlcNAcylated via O-GlcNAcylation transferase, is highly expressed in HCC and facilitated metabolic remodeling to promote the accumulation of products related to uracil metabolism and palmitic acid, driving the progression of HCC. Mechanistically, it is showed that TRIM65 mediates ubiquitylation at the K44 residue of neurofibromatosis type 2 (NF2), the key protein upstream of classical Hippo signaling. Accelerated NF2 degradation inhibits yes-associated protein 1 phosphorylation, inducing aberrant activation of related metabolic enzyme transcription, and orchestrating metabolic and immune advantages. In conclusion, these results reveal a critical role for the TRIM family molecule TRIM65 in supporting HCC cell survival and highlight the therapeutic potential of targeting its E3 ligase activity to alter the regulation of proteasomal degradation.

Citing Articles

Zbtb7b defines a compensatory mechanism in MASLD-related HCC progression by suppressing H19-mediated hepatic lipid deposition.

Han Y, Wu K, Peng X, Fu Y, Li W, Ma J Physiol Rep. 2024; 12(24):e70160.

PMID: 39714087 PMC: 11664540. DOI: 10.14814/phy2.70160.


Tumor‑associated macrophages activated in the tumor environment of hepatocellular carcinoma: Characterization and treatment (Review).

Yu M, Yu H, Wang H, Xu X, Sun Z, Chen W Int J Oncol. 2024; 65(4).

PMID: 39239752 PMC: 11387121. DOI: 10.3892/ijo.2024.5688.


TRIM65/NF2/YAP1 Signaling Coordinately Orchestrates Metabolic and Immune Advantages in Hepatocellular Carcinoma.

Bian Z, Xu C, Wang X, Zhang B, Xiao Y, Liu L Adv Sci (Weinh). 2024; 11(35):e2402578.

PMID: 39005234 PMC: 11425264. DOI: 10.1002/advs.202402578.

References
1.
Zhu G, Tang Z, Huang R, Qu W, Fang Y, Yang R . CD36 cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023; 9(1):25. PMC: 9988869. DOI: 10.1038/s41421-023-00529-z. View

2.
Qi S, Zhong Z, Zhu Y, Wang Y, Ma M, Wang Y . Two Hippo signaling modules orchestrate liver size and tumorigenesis. EMBO J. 2023; 42(11):e112126. PMC: 10233384. DOI: 10.15252/embj.2022112126. View

3.
Mullen N, Singh P . Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer. 2023; 23(5):275-294. PMC: 10041518. DOI: 10.1038/s41568-023-00557-7. View

4.
Wang M, Han J, Xing H, Zhang H, Li Z, Liang L . Dysregulated fatty acid metabolism in hepatocellular carcinoma. Hepat Oncol. 2018; 3(4):241-251. PMC: 6095185. DOI: 10.2217/hep-2016-0012. View

5.
Lu Y, Xiao Y, Yang J, Su H, Zhang X, Su F . TRIM65 Promotes Malignant Cell Behaviors in Triple-Negative Breast Cancer by Impairing the Stability of LATS1 Protein. Oxid Med Cell Longev. 2022; 2022:4374978. PMC: 9402307. DOI: 10.1155/2022/4374978. View